In silico drug repurposing in COVID-19: A network-based analysis
Pasquale Sibilio, Simone Bini, Giulia Fiscon, Marialuisa Sponziello, Federica Conte, Valeria Pecce, Cosimo Durante, Paola Paci, Rosa Falcone, Giuseppe Danilo Norata, Lorenzo Farina, Antonella Verrienti
Abstract
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.